In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy.
Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self …

Oncolytic viruses are a new class of therapeutics which are largely in the experimental
stage, with just one virus approved by the FDA thus far. While the concept of oncolytic …

Chimeric antigen receptor (CAR)–engineered T cell therapy for solid tumors is limited by the
lack of both tumor-restricted and homogeneously expressed tumor antigens. Therefore, we …

Resistance to therapy is a frequently observed phenomenon in the treatment of cancer, and
as with other cancer therapeutics, therapies based on oncolytic viruses also face the …

Background High-mobility group box 1 (HMGB1) is an essential contributor towards initiation
and progression of many kinds of cancers. Nevertheless, our understanding of the molecular …

Triple-negative breast cancer is the most aggressive subtype of breast cancer and is difficult
to treat. Breast cancer is considered to be poorly immunogenic and hence is less responsive …

Background Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma
(PDAC) is fatal. Our preclinical study presents an effective treatment against PDAC PC using …

Oncolytic viruses (OVs) have emerged as one of the most promising cancer immunotherapy
agents that selectively target and kill cancer cells while sparing normal cells. OVs are from …

Virotherapy, a strategy to use live viruses as therapeutics, is a relatively novel field in the
treatment of cancer. With the advancements in molecular biology and virology, there has …

Colon cancer has a high rate of recurrence even with good response to modern therapies.
Novel curative adjuncts are needed. Oncolytic viral therapy has shown preclinical promise …